21:31 , Aug 22, 2019 |  BC Innovations  |  Distillery Therapeutics

Pretreatment with STAT1 activators, IL-10 blocker to improve response to checkpoint inhibitors

DISEASE CATEGORY: Cancer INDICATION: Melanoma; mesothelioma; renal cancer Activating STAT1 and blocking IL-10 prior to checkpoint inhibitor administration could improve efficacy in patients with mesothelioma, melanoma and other cancers. High intratumoral expression of a gene...
17:51 , Aug 21, 2019 |  BC Extra  |  Clinical News

AZ's Imfinzi/tremelimumab combo misses again, this time in another NSCLC

AstraZeneca announced Wednesday that its Imfinzi durvalumab/tremelimumab combination failed to show a survival benefit in first-line non-small cell lung cancer. While the miss marks an end to AZ's recent spate of clinical successes, investors appeared...
11:00 , Aug 21, 2019 |  BC Extra  |  Financial News

Oncorus raises $79.5M series B with eye on global development

Nearly half a dozen Korean investment groups joined Oncorus' $79.5 million series B round as part of the company's long-range plan to take its oncolytic virus technology global. Cowen Healthcare Investments and Perceptive Advisors led...
23:52 , Aug 8, 2019 |  BC Innovations  |  Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...
20:20 , Aug 8, 2019 |  BC Innovations  |  Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

Akrevia is harnessing proteases to mask biologics in the periphery and switch them on when they reach the tumor environment to deliver highly immunostimulatory antibodies, cytokines and other immunotherapies that are otherwise toxic to tissues....
17:18 , Aug 8, 2019 |  BC Innovations  |  Distillery Therapeutics

RNF2 inhibition to treat prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Inhibiting the RNF2 subunit of PRC1 could treat double-negative prostate cancer (DNPC), a subtype of metastatic prostate cancer characterized by a non-responsive androgen receptor pathway and lacking neuroendocrine traits....
23:33 , Aug 2, 2019 |  BC Extra  |  Clinical News

SillaJen, Transgene fall with latest oncolytic virus setback

The failure of Pexa-Vec from Transgene and SillaJen in a Phase III study is the latest blow to the oncolytic virus field, but it may say less about the modality as a whole than about...
04:35 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

Sensitizing cancer to checkpoint inhibitors by targeting the non-coding RNA LINC01139

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Blocking the long non-coding RNA LINC01139 could sensitize checkpoint inhibitor-resistant triple-negative breast cancer (TNBC) to the therapies. High LINC01139 expression levels correlated with low tumor levels of antigen-presenting cells...
01:01 , Jul 24, 2019 |  BC Extra  |  Company News

New flexibility and a new Celgene deal for Jounce

With BMS's acquisition of Celgene nearly complete, the big biotech and Jounce ended an immuno-oncology option deal on Tuesday, giving Jounce control over programs that would have overlapped with BMS's pipeline. But the companies will...
22:34 , Jul 17, 2019 |  BC Extra  |  Financial News

Bayer-backed Pyxis debuts with $22M to pursue new immuno-oncology targets

Pyxis’ tumor microenvironment-based technology to identify immuno-oncology targets developed by cancer researcher Thomas Gajewski prompted Leap by Bayer to lead the start-up’s $22 million series A round. Agent Capital, Ipsen Group (Euronext:IPN; Pink:IPSEY), Longwood and...